Memantina Lannacher Heilmittel (Memantine Hydrochloride)

• Memantina Lannacher Heilmittel (memantine) acts on the glutamatergic pathway and is used for symptomatic management of Alzheimer’s disease.
• Alzheimer’s disease (mild to moderate): modest improvement in memory and thinking.
• Alzheimer’s disease (moderate): supports daily functioning and slows functional decline.
• Alzheimer’s disease (severe): may provide limited symptomatic benefit in cognition and behavior.

• Memantine binds to the phencyclidine site of NMDA receptors as a non‑competitive antagonist, reducing excessive calcium influx caused by glutamate overstimulation. By lowering this excitotoxic activity, it helps preserve neuronal integrity and attenuates synaptic dysfunction associated with Alzheimer’s pathology, thereby providing symptomatic relief without directly altering acetylcholine pathways. The effect is dose‑dependent and reversible, allowing normal neurotransmission at therapeutic concentrations while protecting against pathological over‑activation.

Memantine may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects

• Dizziness: feeling of light‑headedness or unsteadiness.
• Headache: mild to moderate pain in the head region.
• Constipation: reduced bowel movements or hard stools.
• Fatigue: general feeling of tiredness or lack of energy.

Serious or Rare Side Effects

• Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Seizures: increased risk of convulsive episodes.
• Cardiac arrhythmias: irregular heart rhythms, especially in patients with pre‑existing conditions.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential risks.

• Renal impairment: dose may need adjustment; monitor kidney function.
• Hepatic dysfunction: use with caution; assess liver enzymes.
• History of seizures: evaluate risk; monitor for new seizure activity.
• Concomitant use with other NMDA antagonists: avoid additive neuro‑psychiatric effects.
• Pregnancy and lactation: safety not established; avoid unless benefit outweighs risk.
• Store at ambient temperature: keep below 25 °C, in original packaging, protect from moisture and light.

Memantine can interact with several medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., carbamazepine, phenytoin): may lower memantine plasma concentrations.
• Concurrent use with other NMDA antagonists (e.g., amantadine): may increase neuro‑psychiatric toxicity.

Moderate Interactions (Monitor Closely)

• Anticholinergic agents: may blunt cognitive benefits; monitor response.
• Diuretics (e.g., furosemide): may raise serum memantine levels; check renal function.
• Alcohol: may exacerbate dizziness and confusion; advise moderation.